Clinical Trials Directory

Trials / Completed

CompletedNCT02710994

Pharmacodynamics and Safety of CDFR0209

A Randomized, Open Label, Two-way Crossover Designed Clinical Trial to Investigate the Pharmacodynamics and the Safety Between Repeated Doses of CDFR0209 in Healthy Male Volunteers

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
30 (actual)
Sponsor
Ajou University School of Medicine · Academic / Other
Sex
Male
Age
20 Years – 45 Years
Healthy volunteers
Accepted

Summary

This is a randomized, open-label, two-way crossover study to investigate the pharmacodynamics(24 hour gastric pH) and the safety between repeated doses of CDFR0209 and Losec in Healthy Male Volunteers

Detailed description

Eligibility for participation of this study was determined from demographic information, medical history, physical examination, electrocardiogram (ECG) and clinical laboratory tests within 4 weeks before study drug administration. Subjects suitable for this study were admitted to the Clinical Trial Center of Ajou University Medical Center on the 2 day before dosing (Day -2). On Day -1 around 8 AM, ambulatory intragastric pH recording was performed using ZepHr® pH Monitoring System (Sandhill Scientific, Inc., Highlands Ranch, CO, USA) without dosing for 24 hours. On Day 1, subjects was dosed Losec 40 mg or CDFR0209 (Omeprazole 40 mg \& sodium bicarbonate 1,100 mg) around 8 AM and ambulatory intragastric pH recording was continued upto 24 hours after dosing. From Day 2 \~ 6, subjects were dosed Losec 40 mg or CDFR0209 around 8 AM. On Day 7, subjects was dosed Losec 40 mg or CDFR0209 (Omeprazole 40 mg \& sodium bicarbonate 1,100 mg) around 8 AM and ambulatory intragastric pH recording was performed upto 24 hours after dosing. After 14 days of washout period, subjects was dosed Losec 40 mg or CDFR0209 by crossover manner and ambulatory intragastric pH recording was performed.

Conditions

Interventions

TypeNameDescription
DRUGCDFR0209Immediate release omeprazole 40 mg and sodium bicarbonate 1,100 mg
DRUGLosecLosec 40 mg

Timeline

Start date
2014-05-01
Primary completion
2014-08-01
Completion
2015-03-01
First posted
2016-03-17
Last updated
2016-03-17

Locations

1 site across 1 country: South Korea

Source: ClinicalTrials.gov record NCT02710994. Inclusion in this directory is not an endorsement.